What is the practical takeaway

A sensible way to sort these options in 2025 is by how established they are in real knee practice. BMAC and Lipogems-style microfragmented adipose tissue (MFAT) are the two more realistic discussion points now; exosomes still sit much closer to early research. The FDA says there are currently no FDA-approved exosome products, and the published human signal is still small, even though laboratory and animal work is biologically interesting.

For current decision-making, BMAC tends to fit a cautious candidate profile rather than a fixed rule-book: mainly symptomatic mild-to-moderate knee osteoarthritis, and in some joint-preservation cases involving focal cartilage defects. MFAT has a slightly clearer expectation set, with studies showing pain and function improvement through about 12 months, but meta-analyses have not shown a clear advantage over PRP or other injectables. None of these injections should be framed as proven cartilage regrowth treatments; at present, the more defensible expectation is support for symptom relief and the body’s own repair response, with important gaps around standardisation, dosing and long-term durability.

Who may be a reasonable BMAC candidate

A more concrete picture of a BMAC candidate comes from the patients actually studied. BMAC is an autologous marrow-derived biologic used to support a joint-preservation plan, not a guaranteed cartilage-restoration treatment. In current knee OA reviews, the clearest match is a person with symptomatic “mild-to-moderate” osteoarthritis, rather than an all-comers or blanket end-stage arthritis population. The same literature also places BMAC in focal chondral defects, either alongside cartilage-repair procedures or, in some series, as a standalone injection intended to support the local repair environment and symptom control.

That still falls short of a hard eligibility checklist. Across published BMAC studies, the details vary too much: preparation method, delivery approach, injection protocol, and the exact patients selected are not standardised. So the practical read-across is cautious rather than rigid. A knee with earlier-stage degenerative change or a discrete cartilage lesion fits the evidence base more closely; a knee with very advanced structural wear has a weaker evidence footing. The unanswered questions are the important ones: how much BMAC, how it is delivered, which patients benefit most, and whether it performs better over the long term than alternatives such as PRP or other joint-preservation options.

What can you realistically expect from Lipogems

For Lipogems-style microfragmented adipose tissue (MFAT), the useful expectation is usually about pain and function over roughly 12 months, not a dramatic structural reset of the knee. In an observational study of 110 knees, a single ultrasound-guided autologous MFAT injection was followed by improvement in pain, Oxford Knee Score and EQ-5D at 12 months. That fits the broader signal from a 19-study meta-analysis, where scores such as KOOS and pain measures improved after treatment. In other words, published series suggest a knee may feel less irritable and easier to use day to day, but that is different from proving cartilage restoration.

The comparison data are more sobering. A recent meta-analysis found no significant advantage for MFAT over other injectables, including other orthobiologics, hyaluronic acid and corticosteroids, up to 12 months, and the certainty of that evidence was low. In six randomised trials, MFAT and PRP both reached clinically important improvement, with only a small short-term statistical edge for MFAT at around 6 months. So Lipogems is not well supported as the obvious “best” injectable; it sits more as one biologic option among several.

Recovery reporting is thinner than outcome reporting. The 110-knee study reported no adverse events during the intraoperative, recovery or postoperative periods, which is reassuring, but pooled literature also describes mainly mild adverse events rather than none at all. A realistic expectation, then, is a usually manageable recovery burden with a chance of symptom improvement, while the size of benefit, ideal candidate profile and durability beyond the first year remain less certain.

Why are exosomes still a limited option

Exosomes attract interest because they carry signalling molecules that may damp down inflammation and support the body’s own repair processes. That biologic idea is plausible, and a meta-analysis of 28 rat studies found better cartilage-repair scores after MSC-derived exosome treatment. The difficulty is that most of this evidence still sits on the preclinical side. Human data are only just appearing: a small 2025 randomised, double-blind, ascending-dose study reported no adverse consequences and some improvement in clinical scores and MRI, but that remains an early signal rather than proof of established clinical benefit.

The main brakes are regulation, standardisation and follow-up. In the United States, the FDA says there are currently no FDA-approved exosome products. A 2025 clinical-status review also concluded that there is still no peer-reviewed clinical evidence supporting widespread exosome use for symptomatic knee osteoarthritis. Review authors point to the same unresolved gaps: non-standardised isolation and characterisation, product-to-product variability, unclear dosing, and little information on durability. Taken together, that places exosomes closer to an investigational or research-adjacent option than to an established mainstream treatment for knee cartilage damage.

What matters more than the product name

The useful distinction here is not another ranking of BMAC, MFAT and exosomes, but a more practical one: the same product label can hide very different treatments. In the BMAC literature, outcomes mainly come from patients with symptomatic mild-to-moderate knee OA or from focal chondral-defect and joint-preservation settings, while reviews also describe major variation in marrow harvest, processing, delivery and inclusion criteria. Exosome papers have the same problem to an even greater degree; 2025 reviews highlight non-standardised isolation and characterisation, with product-to-product differences in what is actually being injected.

That is why headline comparisons can mislead. One MFAT paper reports a single ultrasound-guided injection in 110 knees; another meta-analysis pools different comparators and follow-up points out to 12 months; some BMAC reports involve cartilage-restoration procedures as well as injection. Those are not clean like-for-like tests, even when the category name sounds identical.

A better filter is the joint problem itself: diffuse osteoarthritis is not the same as a focal defect on MRI, and age, symptom pattern, OA severity, activity goals and response to earlier treatment all shape whether any biologic makes sense. The memorable rule is simple: match the treatment to the knee problem, the protocol and the evidence window, rather than chase the newest label. Across current studies, the firmer expectation is symptom improvement over months, not a proven durable structural fix.

When is a specialist review worth it

A specialist opinion earns its keep once the decision has moved past product labels and towards defining the knee problem on examination and on X-ray or MRI: early osteoarthritis, a focal cartilage lesion, mixed pathology, malalignment, or another pain source. In that setting, a good consultation should cover prior physiotherapy or injections, limb alignment and biomechanics, activity goals, and whether treatment is being considered for symptom control, joint preservation, or as part of a broader plan.

That is usually where the options separate: BMAC tends to enter discussion in selected early-OA or focal-defect cases, MFAT as a biologic option with symptom-improvement data, while exosomes in 2025 remain closer to research than routine care because human evidence is still sparse and the FDA says there are no approved exosome products. For knees that need that level of cartilage and joint-preservation assessment, London Cartilage Clinic on Harley Street offers consultations via londoncartilage.com.

1. [1] Microfragmented Adipose Tissue Has No Advantage Over Platelet-Rich Plasma and Bone Marrow Aspirate Injections for Symptomatic Knee Osteoarthritis: A Systematic Review and Meta-analysis. (2025). https://doi.org/10.1177/03635465241249940 https://doi.org/10.1177/03635465241249940